AA patients with IBC present more frequently with higher stage and triple-negative (TN) [i.e., negative for estrogen (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (ERBB2)] or basal subtype [similar to triple negative, but with epidermal growth factor receptor 1 (EGFR) activation]11, and exhibit shorter median survival (20 months) compared with W patients (32 months)12–16. This evidence concerns the gene ERBB2 and inflammatory breast carcinoma.